The need to implement non-industry COVID-19 clinical trials in non-high-income countries

摘要

The COVID-19 pandemic is currently being managed globally using public health measures to contain and mitigate its impact. The COVID-19 spares no national boundaries and is spreading rapidly in both high-income and non-high-income countries [ ]. The lack of approved therapies and the absence of a vaccine for COVID-19 have led to the repositioning of some existing medications with well-defined benefit-risk profiles in other indications. It is important to note that none of these medications have sufficient evidence on benefit-risk in COVID-19 patients, and should therefore be considered as experimental therapies, with an urgent need to collect data that will facilitate or prevent their use in COVID-19 patients – something that is already happening in many countries [ ].